Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Bianca M.M. Streng, Marin Bont, Eveline M. Delemarre, Rob S. Binnendijk, Gaby Smit, Gerco den Hartog, Antonia M.W. Coppus, Esther de Vries, Michel E. Weijerman, Regina Lamberts, Gert de Graaf, Fiona R. van der Klis, Gestur Vidarsson, Neele Rave, Louis J. Bont, Joanne G. Wildenbeest

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

Samenvatting

The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.

Originele taal-2Engels
Pagina's (van-tot)673-677
Aantal pagina's5
TijdschriftThe Journal of infectious diseases
Volume226
Nummer van het tijdschrift4
DOI's
StatusGepubliceerd - 4 sep. 2022
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome'. Samen vormen ze een unieke vingerafdruk.

Citeer dit